Date | Price Target | Rating | Analyst |
---|---|---|---|
10/8/2021 | $8.00 | Buy | Maxim Group |
Entered into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys Significant Reduction in Overall Operating Expenses of 45.4% in the First Half of 2024 Compared to the First Half of 2023 Conference Call to be Held at 4:30 pm ET on Thursday, August 15, 2024 IRVINE, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial results for the second quarter ended June 30, 2024 and provided a corporate strategic update. Second Quarter 2024 and Subsequent Highlights July 2024: Entered into a definitive merger agreement with Vyom
IRVINE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the second quarter ended June 30, 2024, including a corporate update on Wednesday, August 14, 2024, after market. Management will host a conference call on August 15 at 4:30 pm ET, and will be joined by Krishna K. Gupta, a current Director of Vyome Therapeutics, who will be appointed Chairman of the combined company upon completion of the previously announced merger agreement between the two companies. A live webcast will be available on the "Events and Presenta
CAMBRIDGE, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Vyome Therapeutics, a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, announced today that it has signed a merger agreement with ReShape Lifesciences (NASDAQ:RSLS). Upon closing, it is anticipated that the post-merger entity, will be renamed Vyome Holdings, Inc., and continue to have its common stock traded on Nasdaq under the new ticker symbol "HIND", an ancient name for India, an integral part of Vyome's identity. Anchored in part by Dr. Ranjan Pai, Chairman of the Manipal Education and Medical Group (MEMG), and investors affiliated with Remus C
8-K - ReShape Lifesciences Inc. (0001427570) (Filer)
10-Q - ReShape Lifesciences Inc. (0001427570) (Filer)
425 - ReShape Lifesciences Inc. (0001427570) (Subject)
4 - ReShape Lifesciences Inc. (0001427570) (Issuer)
3 - ReShape Lifesciences Inc. (0001427570) (Issuer)
4 - ReShape Lifesciences Inc. (0001427570) (Issuer)
SC 13D - ReShape Lifesciences Inc. (0001427570) (Subject)
SC 13D - ReShape Lifesciences Inc. (0001427570) (Subject)
SC 13G/A - ReShape Lifesciences Inc. (0001427570) (Subject)
Maxim Group initiated coverage of Reshape Lifesciences with a rating of Buy and set a new price target of $8.00
SAN CLEMENTE, Calif., Aug. 23, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences™ (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the company has appointed Nick Ansari as Senior Vice President of Global Commercial Operations, effective September 6, 2022. Mr. Ansari, who, from 2014 to 2019 was Senior Vice President Global Sales for Enteromedics, the predecessor company to Reshape, will be responsible for strengthening the executional efficiencies of the sales and marketing team, worldwide. In this role, he will report directly to Mr. Paul F. Hickey, ReShape's President and Chief Executive Officer. "Nick is a proven executive
SAN CLEMENTE, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences™ (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Board of Directors has appointed Paul F. Hickey as President and Chief Executive Officer and as a member of the Board of Directors, effective August 15, 2022. Mr. Hickey succeeds Bart Bandy, who has separated from the company to pursue other opportunities. Thomas Stankovich, Chief Financial Officer of ReShape, will serve as Interim President and Chief Executive Officer until Mr. Hickey joins the company. Dan W. Gladney, current Chair of the Board of Directors, will assume a more active role as Exe
SAN CLEMENTE, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced the appointment of Michael Bordainick as its Senior Vice President, Commercial Operations. In this newly created role, as part of the Company's next phase of operational growth, Mr. Bordainick will be responsible for strengthening the strategic development and executional efficiencies of the sales and marketing teams. "As Michael brings significant experience and capabilities to advance ReShape's recently launched commercial programs, including direct-to-consumer marketing and enhanced support for o
IRVINE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the second quarter ended June 30, 2024, including a corporate update on Wednesday, August 14, 2024, after market. Management will host a conference call on August 15 at 4:30 pm ET, and will be joined by Krishna K. Gupta, a current Director of Vyome Therapeutics, who will be appointed Chairman of the combined company upon completion of the previously announced merger agreement between the two companies. A live webcast will be available on the "Events and Presenta
Commercial Launch of Next-Generation Lap-Band® 2.0 FLEX Continues Significant Reduction in Overall Operating Expenses of 51% in the First Quarter of 2024 Compared to the First Quarter of 2023 Implementation of 2024 Cost Reduction Plan Continues, Expected to Reduce Operating Expenses by 55.4% Compared to 2023 Conference Call to be Held at 4:30 pm ET Today IRVINE, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial results for the first quarter ended March 31, 2024 and provided a corporate strategic update. First Quarter 2024 and Subsequent Highlights Ma
IRVINE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the first quarter ended March 31, 2024, including a corporate update on Wednesday, May 15, 2024, after market. Management will host a conference call on May 15 at 4:30 pm ET. A live webcast will be available on the "Events and Presentations" section of ReShape's website at: https://ir.reshapelifesciences.com/events-and-presentations. To access the call by phone, please register with the following Registration Link, and dial-in details will be pro
Maxim Group analyst Anthony Vendetti downgrades Reshape Lifesciences (NASDAQ:RSLS) from Buy to Hold.
Shares of Helen of Troy Limited (NASDAQ:HELE) fell sharply during Tuesday's session after the company reported soft first-quarter earnings and lowered its FY25 guidance. Helen of Troy reported quarterly earnings of 99 cents per share which missed the analyst consensus estimate of $1.59. The company reported quarterly sales of $416.85 million which missed the analyst consensus estimate of $446.22 million, according to data from Benzinga Pro. Helen of Troy shares dipped 30.3% to $62.06 on Tuesday. Here are some other stocks moving in today’s mid-day session. Gainers Soligenix, Inc. (NASDAQ:SNGX) shares jumped 195% to $5.90 after the company announced interim results for extende
Vyome Therapeutics, a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, announced today that it has signed a merger agreement with ReShape Lifesciences (NASDAQ:RSLS). Upon closing, it is anticipated that the post-merger entity, will be renamed Vyome Holdings, Inc., and continue to have its common stock traded on Nasdaq under the new ticker symbol "HIND", an ancient name for India, an integral part of Vyome's identity.Anchored in part by Dr. Ranjan Pai, Chairman of the Manipal Education and Medical Group (MEMG), and investors affiliated with Remus Capital and Iron Pillar, certain of the Company's stockho